Paul Hastings, a leading global law firm, announced today that it represented the joint bookrunners in a US$340 million global depositary receipts (“GDRs”) offering by Hanwha Chemical Corporation, a leading global chemicals company based in Korea that specializes in chemical products and materials for use in the solar power industry. The GDRs will be listed on the Singapore Stock Exchange and the underlying common shares will be listed on the Korea Exchange. More >>
Tags: Paul Hastings LLP
Cahill represented Morgan Stanley and J.P. Morgan as joint book-running managers and BMO Capital Markets as co-lead manager in connection with the Rule 144A offering of $875,000,000 aggregate principal amount of 6.75% Senior Secured Notes due 2019 and $275,000,000 aggregate principal amount of 9.75% Senior Notes due 2020 by Florida East Coast Holdings Corp. and Florida East Coast Industries, LLC. More >>
Tags: Cahill Gordon & Reindel LLP
CMS is advising Wells Fargo Bank N.A. on its funding of the £291 million acquisition by Cirrus Logic, of Wolfson Microelectronics Plc, which was announced yesterday.
Cirrus, which is listed on NASDAQ, is a premier supplier of high-precision analogue and digital signal processing components for audio and energy markets and is a close partner of Apple. Wolfson is a leading UK audio chip designer that supplies audio components in Samsung’s phones and tablets. More >>
Tags: CMS
Herbert Smith Freehills has advised its longstanding client and leading European real estate portfolio and asset managers, AXA Real Estate Investment Managers (“AXA Real Estate”), on the letting of 165,000 square feet of space at its King’s Cross office development scheme to Google on a 15 year lease.
Tags: Herbert Smith Freehills LLP
Global law firm White & Case LLP has advised Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a world leader in musculoskeletal health solutions, in its $13.35 billion acquisition of Biomet, Inc., one of the world’s leading medical device manufacturers. The transaction is expected to close in the first quarter of 2015. More >>
Tags: White & Case LLP | New York
Kirkland & Ellis LLP advised Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), a drug development collaboration company, in its definitive agreement announced today to be acquired by Forest Laboratories, Inc. (NYSE: FRX) for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (or approximately $360 million) in Contingent Value Rights (CVR) that may be payable based on the status of eluxadoline, Furiex’s lead product, as a controlled drug following approval. The acquisition is subject to customary regulatory approvals and approval by Furiex shareholders. More >>
Tags: Kirkland & Ellis LLPLiberty Media Corporation (“Liberty”) (Nasdaq: LMCA, LMCB) today announced the completion of the final closing under the previously announced share repurchase agreement, dated as of October 9, 2013, between Liberty and Sirius XM Holdings Inc. (NASDAQ: SIRI) (“Sirius”). Pursuant to the agreement, Sirius had agreed to repurchase $500 million of its common stock from Liberty as part of Sirius’ share repurchase program. On April 25, 2014, Sirius purchased its final installment of shares, equal to 92,888,561 shares, at a previously established price per share of $3.66, for an aggregate purchase price of $340 million. More >>
Tags: New York
Covington & Burling represented Forest Laboratories in a definitive agreement to acquire Furiex Pharmaceuticals, a drug development collaboration company, for up to $1.46 billion. More >>
Tags: Covington & Burling